top of page

BoobyBiome founders make the 2024 Forbes Under 30 list.

London, UK — April 9, 2024 — BoobyBiome, the pioneering female-founded startup dedicated to revolutionising infant health, proudly announces that its founders have been named in the prestigious Forbes Under 30 list for 2024. This recognition highlights their outstanding contributions to science, healthcare, and entrepreneurship, as well as underscoring their commitment to shaping a healthier future for generations to come.

Founded in 2019 and based at the renowned Great Ormond Street Institute of Child Health, BoobyBiome has embarked on a mission to bridge the gap in infant feeding and ensure every baby, regardless of their feeding method, reaps the benefits of the breast milk microbiome. Through cutting-edge research and innovative products, BoobyBiome aims to strengthen infant immune defences and promote lifelong health.

Dr. Sioned Jones, Chief Operating Officer, Dr. Tara O’Driscoll, Chief Technology Officer, and Dr. Lydia Mapstone, Chief Executive Officer, bring a wealth of expertise in microbiology, neuroscience, chemistry, and biophysics from esteemed institutions such as University College London and King’s College London. Their journey began with a profound concern for the rising incidence of infant diseases linked to inadequate microbiome development, propelling them to explore the transformative potential of the breast milk microbiome.

For over five years, BoobyBiome has been at the forefront of research, establishing the world's first breast milk microbiome database and biobank. Through the generosity of hundreds of women who donated their breast milk, the company has made groundbreaking strides in understanding and harnessing the power of breast milk bacteria. This innovative work has garnered widespread recognition, with features on far reaching platforms including BBC and Channel 4.

BoobyBiome’s commitment to innovation and scientific excellence has been further validated by securing over £2 million in prestigious grant awards, including the Innovate UK Biomedical Catalyst, Smart Grant, and Women in Innovation. Additionally, the company has attracted support from top-tier investors such as Venrex and Discovery Park Ventures, enabling the realisation of their ambitious vision.

The company's forthcoming product, a baby bottle accessory designed to preserve the natural breast milk microbiome and extend shelf life, marks the beginning of a new era in infant nutrition. BoobyBiome is also developing a revolutionary microbiome supplement enriched with bacteria isolated from breast milk, coupled with prebiotic sugars, to enhance the health outcomes of formula-fed, c-section-born, or preterm babies.

With these innovative solutions and a steadfast commitment to equitable access to infant health, BoobyBiome is poised to redefine standards in paediatric care and pave the way for a healthier future for all babies.


bottom of page